Neuromodulation for Behavioral Changes in Neurological Disorders

• Age 45-80 years at time of enrollment.
• Diagnosis of probable mild-stage neurodegenerative dementia, including Alzheimer's disease (AD), frontotemporal dementia (FTD, including behavioral variant and language variant), or dementia with Lewy bodies (LBD), based on established consensus clinical criteria.
• Presence of clinically meaningful (in treatment for or recommended for the symptoms) neuropsychiatric or behavioral symptoms including but not limited to anxiety, agitation, depression, irritability, apathy, or disinhibition
• Able to undergo MRI scanning
• Adequate auditory and visual abilities to complete study procedures as determined by the investigator.
• Availability of a study partner (legally authorized representative, caregiver, or family member) who has regular contact with the participant and can provide collateral information and assist with assessments.
• Ability to provide informed consent, or assent with legally authorized representative (LAR) consent in accordance with WVU IRB policy and applicable West Virginia law. .Currently under the care of a licensed physician, psychiatrist, or neurologist, and agrees to allow communication between investigators/study staff and healthcare providers for purposes of eligibility confirmation and safety monitoring.

EXCLUSION CRITERIA

• Moderate to severe dementia (i.e., beyond mild stage).
• Clinically significant MRI abnormality that may jeopardize participant safety, study conduct, or confound diagnostic assessments.
• History of clinically significant neurological disorder other than the qualifying dementia diagnosis that could confound evaluation or increase risk.
• Major psychiatric disorder that would interfere with participation or safety, including psychosis, active suicidal ideation, or severe mood/anxiety disorder requiring immediate intervention.
• Elevated suicide risk with History of medically verified suicide attempt within the past year.
• Use of medications that significantly lower the seizure threshold or interfere with neuromodulation safety, as determined by the study physician.
• Use of investigational drugs or participation in another interventional clinical trial within 30 days prior to screening.
• Any condition that, in the opinion of the investigator, would interfere with study participation, safety, or interpretation of results.